Skip to main content
Premium Trial:

Request an Annual Quote

RXi Obtains Three-Year Option to License UMMS Therapeutic RNAi IP

NEW YORK (GenomeWeb News) - RXi Pharmaceuticals has signed a three-year agreement with the University of Massachusetts Medical School that will allow the company to license all unrestricted therapeutic RNAi technology the school develops during that period, RXi parent company CytRx said today.
 
RXi said it licensed the UMMS technology for a combination of "cash and equity." Details of the financial terms were not provided.
 
The company said UMMS has disclosed new, unrestricted RNAi technologies, and that the agreement gives it the right to negotiate “on an exclusive basis" with UMMS to obtain a license for worldwide use of the technology "on commercially reasonable terms."
 
The option rights depend upon RXi's receipt of working capital funding in the coming months, the company added.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.